🕒 Last update: loading…

Stock Xvivo Perfusion AB (publ) XVIVO.ST

Xvivo Perfusion AB (publ) — Investlytic score 3/5 on the five criteria.

-
-
60/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 3/5 criteria met.

  • ✅ Price trend passed
  • ✅ Growth passed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 28.79%

Price change 2019 → 2020: 84.71%

Price change 2020 → 2021: -11.31%

Price change 2021 → 2022: -34.29%

Price change 2022 → 2023: 80.05%

Price change 2023 → 2024: 48.41%

Price change 2024 → 2025: -61.84%

Price change 2025 → 2026: 16.72%

Price change 2026 (year to date): 20.27%

Financial growth

Revenue CAGR (8 years): 23.26%

Earnings CAGR (8 years): 10.28%

Growth status: positive trend (>1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 0.06

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 74.56

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 29.51% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Xvivo Perfusion AB (publ)48.00.06+36.1 %🔒
4D Molecular Therapeutics, Inc.–0.04+40.0 %–
Lumibird S.A.38.10.71+9.8 %–
National Research Corporation31.55.65+5.3 %–
Valneva SE–1.95+22.4 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Xvivo Perfusion AB (publ) over the latest fiscal years.

Revenue
80.6 m USD
fiscal year 2025
Net income
2.5 m USD
fiscal year 2025
Net margin
3.1 %
fiscal year 2025
Average annual growth
+35.2 %
Revenue growth over 5 years
Average annual growth
+21.0 %
Revenue growth over 10 years
Market cap
644 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202017.9 m-4.3 m-24.3 %n/a
202125.7 m809,3003.1 %+43.7 %
202241.2 m1.8 m4.4 %+60.7 %
202359.3 m9.1 m15.4 %+43.9 %
202481.6 m17.1 m20.9 %+37.6 %
202580.6 m2.5 m3.1 %-1.2 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Xvivo Perfusion AB (publ) over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
solid accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
12.87
safe zone (above 2.99)
Piotroski Score
6 / 9
4 to 6: average accounts
Net Debt / EBITDA
-0.90 x
net cash
Fiscal year20212022202320242025
Cash and investments399 m247 m546 m416 m292 m
Total Debt5.7 m10.0 m31.4 m34.0 m125 m
Net Debt-393 m-237 m-514 m-381 m-167 m
Equity1.3 bn1.4 bn1.9 bn2.2 bn2.1 bn
Total assets1.5 bn1.7 bn2.2 bn2.4 bn2.4 bn
Operating cash flow-12.1 m27.9 m46.3 m111 m101 m
Investments (capex)94.1 m131 m43.0 m193 m101 m
Free cash-flow-106 m-103 m-97.6 m-81.9 m-152 m
Share buybacks0368,000000
Dividends paid00000

Amounts in SEK, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)49.58 x
Price / book value2.82 x
Return on Equity (ROE)5.9 %
Return on Invested Capital (ROIC)4.2 %
Net margin13.4 %
Debt / equity0.05 x
Current ratio3.91 x
Interest coverage-12.52 x
Free cash-flow yield3.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.

+

Valuation and competitors

Xvivo Perfusion AB (publ) compared with its sector on the same exchange and with its main competitors.

Company P/E
50.1

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

Xvivo Perfusion AB (publ): dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
22/10/20261.390.64+116.2 %
14/07/20260.520.75-31.0 %
24/04/20261.150.94+21.8 %
27/01/20261.050.68+53.5 %
23/10/20250.260.44-41.2 %
11/07/20250.050.62-91.9 %

Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Xvivo Perfusion AB (publ).

Free float
79.8 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
likely
head office in the EU or EEA, listed on a European exchange
Listing exchange
Nasdaq Stockholm
IPO: 08/10/2012
ISIN code
SE0004840718
Workforce
193
full-time employees
Chief executive
Christoffer Rosenblad

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Xvivo Perfusion AB (publ)

What is the Xvivo Perfusion AB (publ) share price?

Latest recorded price: 206.00 SEK on 13/11/2026, for a market cap of 644 m USD.

What is the revenue of Xvivo Perfusion AB (publ)?

80.6 m USD for fiscal year 2025, with net income of 2.5 m USD (net margin 3.1 %).

What is the P/E ratio of Xvivo Perfusion AB (publ)?

Trailing 12-month P/E of 50.1.

Is Xvivo Perfusion AB (publ) stock eligible for the French PEA?

Likely: the company is headquartered in the European Union or the European Economic Area (ISIN SE0004840718) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.

How many employees does Xvivo Perfusion AB (publ) have?

193 full-time employees according to the latest published profile.

Who runs Xvivo Perfusion AB (publ)?

Christoffer Rosenblad is the company's chief executive.

07

Similar stocks